Meeting
2019 ASCO Annual Meeting
Survival by stage and tumor measurability in metastatic melanoma patients treated with autologous dendritic cell tumor cell vaccines.
Authors
Robert O. Dillman
AIVITA Biomedical, Irvine, CA
Robert O. Dillman , Andrew N Cornforth , Edward Francis McClay , Carol DePriest
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Vaccines
Clinical Trial Registration Number
NCT00948480, NCT00436930
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2637)
DOI
10.1200/JCO.2019.37.15_suppl.2637
Abstract #
2637
Poster Bd #
281
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
5-year follow up for 72 metastatic melanoma patients treated with eltrapuldencel-T (CLBS20) vaccine.
First Author: Robert O. Dillman
Poster
2023 ASCO Annual Meeting
Association of ultra-sensitive ctDNA assay to identify actionable variants and response to immune checkpoint inhibitor (ICI) therapy in metastatic melanoma.
First Author: Christoffer Gebhardt
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Metronomic oral cyclophosphamide as maintenance therapy in metastatic pancreatic ductal adenocarcinoma.
First Author: Michele Reni
Poster
2022 ASCO Annual Meeting
The prognostic impact of immune-related adverse events in real-world patients with metastatic melanoma treated with single-agent and combination immune checkpoint blockade.
First Author: Alexander Watson